ASCO 2021 | PrE0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with MIBC

Petros Grivas, MD, PhD, University of Washington School of Medicine & Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the results of the PrE0807 trial (NCT03532451), which evaluated the anti-programmed death-1 (PD-1) checkpoint inhibitor nivolumab and killer cell immunoglobulin-like receptor (KIR) inhibitor lirilumab in the neoadjuvant setting for patients with muscle-invasive bladder cancer (MIBC) who could not receive cisplatin or refused cisplatin therapy. Overall, the treatment was considered safe and feasible, with no Grade 3 or higher adverse events for nivolumab alone; only Grade 3 adverse events for the combination approach and no delay for the radical cystectomy (RC). The pathologic complete response rate was 8% for nivolumab alone and 18% for nivolumab/lirilumab. The pathologic partial response rate was 17% for nivolumab alone and 29% for nivolumab/lirilumab. The response rates were lower than expected, however a follow up of data with further biomarker study is expected. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.